Investigational drug · Phase 2
IOV-3001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IOV-3001"
First trial start
2025
Mar 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IOV-3001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Melanoma
- Metastatic Melanoma
- Ocular Melanoma
Approved drugs for the same conditions: Melanoma · Oncology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "IOV-3001" as an intervention, largest first.
Iovance Biotherapeutics, Inc.Industry
NCT06940739 · 42 participants (planned) · Start Mar 11, 2025 · Primary completion Jun 2032
Drug: IOV-3001 · For: Unresectable Melanoma; Metastatic Melanoma; Ocular Melanoma
Sites: Denver, Colorado; Chapel Hill, North Carolina; Nashville, Tennessee · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Unresectable Melanoma
- IO102-IO103Phase 33 trials
IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma
- ipilimumab and nivolumabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- LNS8801Phase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- nivolumab and relatlimabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- EVX-01Phase 21 trial
Evaxion Biotech A/S · Melanoma Stage IV, Unresectable Melanoma
- IOV-4001Phase 21 trial
Iovance Biotherapeutics, Inc. · Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.